Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

By K. Shoghi-Jadid, G. Small, Eric Agdeppa, V. Kepe, L. Ercoli, P. Siddarth, S. Read, N. Satyamurthy, A. Petrič, Sung-Cheng Huang and 1 more. The American journal of geriatric psychiatry, 2002

771 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/cf2c4967f0d8ff0b837d2882c888ee14bc1496d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. (2006, background): “Owing to the limitations of post-mortem brain studies, several attempts have been made to develop tracers for in vivo imaging of amyloid, and three compounds have been applied in PET studies in Alzheimer patients (Shoghi-Jadid et al., 2002; Klunk et al., 2004; Verhoeff et al., 2004).”
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005, methodology): “Radiotracers with high affinity of amyloid (in A plaques) have been developed recently for use in humans (Kung et al., 2002; Shoghi-Jadid et al., 2002; Mathis et al., 2003).”
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (2004, methodology): “The second in vivo human amyloid-imaging study used the tracer (18)F-FDDNP to quantify amyloid in nine AD patients and seven controls.(51) The time-activity data from an AD patient included in that study indicated that, at late time points (90 –120 minutes), the absolute retention of (18)F-FDDNP in ”